Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial.
Oncologist
; 28(12): e1259-e1267, 2023 Dec 11.
Article
in En
| MEDLINE
| ID: mdl-37338150
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neoplasms
/
Antineoplastic Agents
Limits:
Adult
/
Humans
Country/Region as subject:
Asia
Language:
En
Journal:
Oncologist
Journal subject:
NEOPLASIAS
Year:
2023
Type:
Article